Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin. (PubMed, Leukemia) - Oct 10, 2026 - "Multivariable analyses identified a ≥25% reduction in the KIT D816V allele burden (midostaurin), normalization of serum albumin levels (avapritinib), and normalization of hemoglobin and/or platelet levels (midostaurin and avapritinib) within 6 months as significant predictors for prolonged OS. In conclusion, genetic profiling, dynamic laboratory parameters, and KIT D816V monitoring improve outcome prediction in patients with AdvSM on midostaurin or avapritinib."
Journal • ASXL1 • RUNX1 • SETBP1 • SRSF2
|
|
Andreas Reiter; Daniel J DeAngelo; Deepti H Radia; Hongliang Shi; Ilda Bidollari; Jason Gotlib; Javier I Muñoz-González; Johannes Lübke; Juliana Schwaab; Michael Deininger; Tracy I George
|